Mayne Pharma Group Limited (ASX: MYX) - ETF Exposure

- Current share price for MYX : $3.150

Mayne Pharma Group Limited (MYX) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is an ASX-listed specialty pharmaceutical company focused on commercializing branded women's health and dermatology pharmaceuticals.

MYX General Information ⁺

ASX Code	MYX
Website	http://maynepharma.com
Industry/Sector	Pharmaceuticals
Market Cap ($M)	255
MYX Share Price	$3.150
Day High	$3.195
Day Low	$2.980
Last Close	$3.150
MYX Share Price Movement	- ( No change )

Prices as at 16:40, 7 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to MYX

Mayne Pharma Group Limited (MYX) is held across 5 ETFs spanning strategies that include pharmaceuticals exposure . Its weighting in those funds means performance can have an outsized influence - when MYX moves, funds like DACE that hold it can move with it.

For more concentrated exposure, ETFs such as DACE (Dimensional Australian Core Equity (Managed Fund)) allocate about 0% to MYX , while the average exposure across all 5 ETFs that hold it is around 0% .

Top ETF holdings

Dimensional Australian Core Equity (Managed Fund) (DACE) ~ 0%

Last updated: ETF data and holdings as at 9 August 2026

Own MYX directly or through an ETF?

How does holding Mayne Pharma Group Limited (MYX) shares directly compare to ETFs that include it?

	MYX Direct	DACE ASX
Holdings	1 company	470 holdings
MYX Weight	100%	0%
Diversification	Single Stock	Broad
Annual Cost	Brokerage only	0.28% p.a.
Approx. Yield	-	2.93%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not MYX's direct yield. Annual cost uses each ETF's MER.

MYX Exposure on $10,000 investment

How a $10,000 investment in Mayne Pharma Group Limited (MYX) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Mayne Pharma Group Limited (MYX)	Direct share	$3.150	18.42%	+$1,842	$11,842
Dimensional Australian Core Equity (Managed Fund) (DACE)	Equity - Australia Strategy	$19.500	3.89%	+$389	$10,389

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Mayne Pharma Group Limited (MYX) ETFs

5 ETFs hold Mayne Pharma Group Limited (MYX).

ETF	MYX Weight	MER	Yield
Dimensional Australian Core Equity (Managed Fund) (DACE)	0%	0.28%	2.93%

View all 5 ETFs

Mayne Pharma Group Limited (MYX) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
Result	2.72¢	100%	18 Jan 2023	27 Jan 2023	-	-	-
Interim	1¢	100%	3 Mar 2011	25 Mar 2011	-	-	-
Final	2¢	100%	25 Oct 2010	18 Nov 2010	-	-	-

See all dividends from Mayne Pharma Group Limited (MYX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Mayne Pharma Group Limited (MYX) price-sensitive announcements

MYX - Mayne Pharma reports unaudited Q4 and FY26 results

Mayne Pharma Group Limited reported its unaudited financial results for the fourth quarter

Mayne Pharma Group Limited (MYX)
31 Jul 2026 | 9:29 AM

MYX - Mayne Pharma receives $14.4m for legal costs from Cosette

On June 5, 2026, Mayne Pharma Group Limited announced receiving $14.4 million from Cosette

Mayne Pharma Group Limited (MYX)
5 Jun 2026 | 10:44 AM

MYX - Court awards MYX $13.27m for legal costs from Cosette

Mayne Pharma Group Limited has been awarded $13.27 million in legal costs by the Supreme C

Mayne Pharma Group Limited (MYX)
22 May 2026 | 11:08 AM

MYX - Mayne Pharma reports unaudited 3Q FY26 results

Mayne Pharma Group Limited reported its unaudited 3Q FY26 results, highlighting a successf

Mayne Pharma Group Limited (MYX)
29 Apr 2026 | 9:33 AM

Mayne Pharma Group Limited (MYX) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Mayne Pharma Group Limited (MYX) ORDINARY FULLY PAID	Health Care	$256	Mayne Pharma Bioshares Summit Presentation	5 Aug 2026 5:20PM	$3.130	$3.150	risen by 0.64%
Mayne Pharma Group Limited (MYX) ORDINARY FULLY PAID	Health Care	$256	Notification of cessation of securities - MYX	5 Aug 2026 5:14PM	$3.130	$3.150	risen by 0.64%
Mayne Pharma Group Limited (MYX) ORDINARY FULLY PAID	Health Care	$256	Notification regarding unquoted securities - MYX	5 Aug 2026 5:14PM	$3.130	$3.150	risen by 0.64%
Mayne Pharma Group Limited (MYX) ORDINARY FULLY PAID	Health Care	$256	Non-Executive Director appointment	5 Aug 2026 1:35PM	$3.030	$3.150	risen by 3.96%
Mayne Pharma Group Limited (MYX) ORDINARY FULLY PAID	Health Care	$256	Mayne Pharma to present at the 20th Bioshares Summit	3 Aug 2026 3:46PM	$2.920	$3.150	risen by 7.88%
Mayne Pharma Group Limited (MYX) ORDINARY FULLY PAID	Health Care	$256	Mayne Pharma reports unaudited Q4 and FY26 results	31 Jul 2026 9:29AM	$2.600	$3.150	risen by 21.15%

MYX Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2027F	C2	-$27.50	-47.20%	0.00%	0.0%
2026F	C2	-$52.10	-46.00%	0.00%	0.0%
2025A	-$76.40	-$96.50	-42.30%	0.00%	0.0%

MYX Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F
Clarity Pharmaceuticals Ltd (CU6)	$1,000M	0.3002	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Mayne Pharma Group Limited (MYX)	$252M	-0.4227	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,733M	-0.7857	0.2462	0.9655	92.6515	74.3448	37.8246	0.00%	0.00%	0.00%

MYX Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	0.69	0.00
Market	0.61	18.00	1.68	1.05
Sector	0.49	33.50	2.47	2.59

MYX Directors

Name	Position	Start Date
Ms Ann Custin	Non-Executive Director	23 Mar 2022
Mr David Petrie	Non-Executive Director	1 Sep 2022
Ms Meghan Rivera	Non-Executive Director	26 Jun 2026
Professor Bruce Gregory Robinson AC	Non-Executive Director, Non-Executive Chairman	26 Aug 2014

Mayne Pharma Group Limited (MYX) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
18 Dec 2025	O'BRIEN, Shawn	Sell	Indirect Shares	129,736	$3.094	$401,341.040
1 Dec 2023	CONDELLA, Frank	Buy	Direct Shares	7,154	$5.425	$38,811.460
25 Oct 2023	MACFARLANE, Kathryn	Buy	Direct Shares	18,000	$3.840	$69,120.000

See all changes in directors' interest & trades for Mayne Pharma Group Limited (MYX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

MYX Management

Name	Position
Aaron Gray	Chief Financial Officer
Laura Loftus	Company Secretary

MYX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Mayne Pharma Group Limited (MYX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
6,743,487 (8.30%)	The Goldman Sachs Group, Inc.
5,292,066 (6.51%)	Bruce Mathieson
4,986,922 (6.14%)	UBS Group AG and its related bodies corporate
4,356,426 (5.36%)	Rubric Capital Management LP

MYX Calendar of Events

Date	Event
22 February 2027	Report (Interim)
13 October 2026	Report (Annual)
28 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us